Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287368 | 0.94 | MIF (0.34) | MAPTLMNAPOLBMIFSMN1; SMN2 | |
| SCHEMBL661855 | 0.89 | LMNA (0.33) | MAPTLMNAPOLBMIF | |
| SCHEMBL27473615 | 0.67 | LMNA (0.31) | MAPTLMNAPOLBMIF | |
| SCHEMBL11213610 | 0.66 | KMT2A (0.49) | MAPTLMNAPOLBMIFSMN1; SMN2 | |
| SCHEMBL6694136 | 0.63 | ALDH1A1 (0.56) | MAPTLMNAPOLBMIFSMN1; SMN2 | |
| SCHEMBL287385 | 0.63 | ALDH1A1 (0.46) | MAPTPOLBSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL660129 | 0.61 | GAA (0.46) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL2789975 | 0.61 | MAPT (0.48) | MAPTLMNAMIFSMN1; SMN2MEN1 | |
| SCHEMBL1844829 | 0.60 | MIF (0.43) | MAPTLMNAPOLBMIFSMN1; SMN2 | |
| SCHEMBL298992 | 0.60 | ALDH1A1 (0.38) | MAPTLMNAPOLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | MAPT 61/4885LMNA 123/4885POLB 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.